Lenz announces CORXEL submitted NDA for LNZ100 in China

LENZ Therapeutics (LENZ) announced that CORXEL Pharmaceuticals has submitted the New Drug Application, NDA, for LNZ100 to the Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC. LENZ licensed the Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022. The submission of the NDA for LNZ100 results in the achievement of the first milestone under the License and Collaboration Agreement with CORXEL. Under the terms of the License, LENZ is eligible to receive up to $95.0 million of regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China.